

CLAIMS

1. A therapeutic agent for treatment of acute lung injury resulting from indirect causes comprising anti-IL-8 antibody as an active ingredient.

2. The therapeutic agent according to claim 1 in which the acute lung injury is acute respiratory distress syndrome.

3. The therapeutic agent according to claim 1 in which the acute lung injury is adult respiratory distress syndrome.

4. The therapeutic agent according to any of claims 1, 2, and 3, in which the indirect cause is the sepsis syndrome.

5. The therapeutic agent according to any of claims 1, 2, and 3, in which the indirect cause is severe nonthoracic trauma.

6. The therapeutic agent according to any of claims 1, 2, and 3, in which the indirect cause is hypertransfusion during emergency resuscitation.

7. The therapeutic agent according to any of claims 1, 2, and 3, in which the indirect cause is artificial cardiopulmonary bypass surgery.

8. The therapeutic agent according to ^{claim 1} ~~any of~~ ~~claims 1 through 7~~, in which the anti-IL-8 antibody is a monoclonal antibody.

9. The therapeutic agent according to ^{claim 1} ~~any of~~ ~~claims 1 through 8~~, in which the anti-IL-8 antibody is an antibody against mammalian IL-8.

10. The therapeutic agent according to ^{claim 1} ~~any of~~ ~~claims 1 through 9~~, in which the anti-IL-8 antibody is an antibody against human IL-8.

11. The therapeutic agent according to ^{claim 1} ~~any of~~ ~~claims 1 through 10~~, in which the anti-IL-8 antibody is WS-4 antibody.

12. The therapeutic agent according to ^{claim 1} ~~any of~~ ~~claims 1 through 11~~, in which the anti-IL-8 antibody has the constant region of human antibody.

a
a
13. The therapeutic agent according to ^{claim 1} ~~any of~~ ~~claims 1 through 12~~, in which the anti-IL-8 antibody is a humanized or chimeric antibody.

Q
5 14. The therapeutic agent according to ^{claim 1} ~~any of~~ ~~claims 1 through 13~~, in which the anti-IL-8 antibody is a humanized WS-4 antibody.

15. A therapeutic agent for hypoxemia in acute lung injury resulting from indirect causes comprising anti-IL-8 antibody as an active ingredient.

Sub 7
B2
10 16. Use of anti-IL-8 antibody for production of a therapeutic agent for treatment of acute lung injury resulting from indirect causes.

a
17. ^{A process} ~~Use~~ according to claim 16 in which the acute lung injury is acute respiratory distress syndrome.

15 18. ^{A process} ~~Use~~ according to claim 16 in which the acute lung injury is adult respiratory distress syndrome.

19. ^{A process} ~~Use~~ according to any of claims 16, 17, and 18, in which the indirect cause is the sepsis syndrome.

20 20. ^{A process} ~~Use~~ according to any of claims 16, 17, and 18, in which the indirect cause is severe nonthoracic trauma.

21. ^{A process} ~~Use~~ according to any of claims 16, 17, and 18, in which the indirect cause is hypertransfusion during emergency resuscitation.

a
25 22. ^{A process} ~~Use~~ according to any of claims 16, 17, and 18, in which the indirect cause is an artificial cardiopulmonary bypass surgery.

Sub 7
Q2
23. Use according to any of claims 16 through 22, in which the anti-IL-8 antibody is a monoclonal antibody.

30 24. Use according to any of claims 16 through 23, in which the anti-IL-8 antibody is an antibody against mammalian IL-8.

25. Use according to any of claims 16 through 24, in which the anti-IL-8 antibody is an antibody against human IL-8.

35 26. Use according to any of claims 16 through 25, in which the anti-IL-8 antibody is WS-4 antibody.

27. Use according to any of claims 16 through 26,

Sub 2
in which the anti-IL-8 antibody has the constant region of human antibody.

28. Use according to any of claims 16 through 27, in which the anti-IL-8 antibody is a humanized or
5 chimeric antibody.

29. Use according to any of claims 16 through 28, in which the anti-IL-8 antibody is a humanized WS-4 antibody.

30. Use of anti-IL-8 antibody for production of a
10 therapeutic agent for hypoxemia in acute lung injury resulting from indirect causes.

31. A therapeutic method for treatment of acute lung injury resulting from indirect causes, which method comprises administering anti-IL-8 antibody to a subject in need of said therapy.
15

32. The method according to claim 31 in which the acute lung injury is acute respiratory distress syndrome.

33. The method according to claim 31 in which the acute lung injury is adult respiratory distress syndrome.
20

34. The method according to any of claims 31, 32, and 33, in which the indirect cause is the sepsis syndrome.

35. The method according to any of claims 31, 32, and 33, in which the indirect cause is severe nonthoracic trauma.
25

36. The method according to any of claims 31, 32, and 33, in which the indirect cause is hypertransfusion during emergency resuscitation.

37. The method according to any of claims 31, 32, and 33, in which the indirect cause is an artificial cardiopulmonary bypass surgery.
30

38. The method according to ^{claim 31} ~~any of claims 31 through 37~~, in which the anti-IL-8 antibody is a monoclonal antibody.

39. The method according to ^{claim 31} ~~any of claims 31 through 38~~, in which the anti-IL-8 antibody is an antibody against mammalian IL-8.
35

40. The method according to ^{claim 31} ~~any of claims 31 through 39~~, in which the anti-IL-8 antibody is an antibody against human IL-8.

41. The method according to ^{claim 31} ~~any of claims 31 through 40~~, in which the anti-IL-8 antibody is WS-4 antibody.

42. The method according to ^{claim 31} ~~any of claims 31 through 41~~, in which the anti-IL-8 antibody has the constant region of human antibody.

43. The method according to ^{claim 31} ~~any of claims 31 through 42~~, in which the anti-IL-8 antibody is a humanized or chimeric antibody.

44. The method according to ^{claim 31} ~~any of claims 31 through 43~~, in which the anti-IL-8 antibody is a humanized WS-4 antibody.

45. Use of anti-IL-8 antibody for production of a therapeutic agent for hypoxemia in acute lung injury resulting from indirect causes.